Skip to main content

Market Overview

Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts

Share:
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts

Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:SAGE) that it does not already owned by Biogen for $7.22 per share.

Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).

Biogen says Zurzuvae exceeded its expectations.

Also Read: Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Goldman Sachs estimates Zurzuvae could reach global peak sales of approximately $700 million for PPD by 2034.

Richter notes that investors remain focused on Biogen’s growth strategies. This includes expanding its pipeline, pursuing external business development, or leveraging new opportunities to counter declining revenue in the latter half of the decade.

During the third quarter earnings call, management highlighted the potential for an $8 billion to $10 billion deal within the next two years, primarily focusing on rare diseases and immunology.

They also emphasized continued interest in neurology while acknowledging the strength of Biogen’s immunology capabilities from its multiple sclerosis franchise and the need to diversify further.

William Blair has consistently seen Zurzuvae’s role in treating postpartum depression as less significant to Biogen’s overall value. Instead, the firm prioritizes the progress of Biogen’s late-stage programs and improvements in Leqembi’s treatment profile.

Analyst Myles Minter suggests that while the deal may not boost Biogen’s stock, it provides a smart strategy for marketing Zurzuvae and maximizing its value.

If the deal is finalized, Biogen should consider acquiring more companies in the neuropsychiatry field to strengthen its collaboration with Zurzuvae, Minter says.

Price Action: Biogen stock is up 0.34% at $150.32 at last check Monday.

Read Next:

Image: Shutterstock

Latest Ratings for BIIB

DateFirmActionFromTo
Mar 2022StifelDowngradesBuyHold
Mar 2022RBC CapitalUpgradesSector PerformOutperform
Feb 2022Canaccord GenuityMaintainsBuy

View More Analyst Ratings for BIIB

View the Latest Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech M&A News Health Care Top Stories Analyst Ratings General

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com